Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 9 Nov 2004 |
| Publication schedule for Orion?s financial reporting in 2005 | 9 Nov 2004 |
| 100,000 Orion A-shares converted into B-shares | 8 Nov 2004 |
| Orion Corporation appoints a nomination committee | 8 Nov 2004 |
| Orion Corporation applies for the listin | 20 Sept 2004 |